Medtech Companies Face Challenges And Choices When Going Public
In a panel discussion at The Medtech Conference, hosted by AdvaMed, CEOs discussed the challenges, benefits and technicalities surrounding an IPO.
You may also be interested in...
“It’s going to be industry people like me that have to make a decision that we're going to spend the time, we're going to spend the money to work with FDA for the many years it takes generally speaking to get these things approved,” says Femasys CEO Kathy Lee-Sepsick.
The CONCERTO trial will evaluate the company’s SING IMT, an upgrade of its 12-year-old WA IMT device, in up to 100 people in the US with age-related macular degeneration.
Novalis Biotech employs early targeted investments to produce returns, focusing on enabling technologies and risky ventures in diagnostics and digital health.